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Abstract
AIM
To evaluate the potential association between mild 
duodenal damage and microscopic colitis (MC).
METHODS 
We retrospectively included 105 consecutive patients 
with type I Marsh-Oberhuber duodenal damage and 
negativity for immunoglobulin A anti-endomysium and 
anti-tissue transglutaminase. The following parameters 
were analyzed: Sex, age at execution of esophago-
gastroduodenoscopy, duodenal damage, and number 
of intraepithelial lymphocytes at biopsies, prevalence 
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Retrospective Study
of Helicobacter pylori  infection, age at execution of 
colonoscopy, macroscopic and microscopic features 
of colonoscopy, family history of gastrointestinal and 
autoimmune diseases, smoking habits, biochemical 
parameters of inflammation and autoimmunity, use of 
proton pump inhibitors or nonsteroidal anti-inflammatory 
drugs, adverse reactions to drugs or foods, pathologies 
known to be associated with celiac disease or MC, living 
on a gluten-free diet or on a gluten-low diet for at least 
1 mo. 
RESULTS
Colonoscopy was performed in 59 patients, but only 
in 48 of them biopsies were taken in the entire colon. 
Considering the latter cohort, the diagnosis of MC was 
met in 25 (52.1%) patients while in 18 patients other 
pathologic findings were reported: 13 (27%) cases 
of nonspecific inflammatory bowel disease, 2 (4.2%) 
cases of Crohn’s disease, 2 (4.2%) cases of eosinophilic 
gastroenteritis, and 1 (2.1%) case of autoimmune 
enteritis. Five (10.4%) patients had a normal colono-
scopic result. Matching the groups by age, and con-
sidering only patients who underwent colonoscopy (42.7 
± 15.5 years) vs those who did not undergo colonoscopy 
(36.9 ± 10.6 years), a statistical difference was found 
(P  = 0.039). Focusing on symptoms, diarrhea was 
statistically more prevalent in MC group than in patients 
who did not undergo colonoscopy (P  = 0.03). 
CONCLUSION
Mild duodenal damage is associated with MC in more 
than half of the cases. This association supports the 
hypothesis of a link between these two entities.
Key words: Autoimmune diseases; Celiac disease; 
Helicobacter pylori ; Intraepithelial lymphocytes; Lym-
phocytic colitis; Lymphocytic enterocolitis; Microscopic 
colitis
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Core tip: Scarce information is available on patients 
with symptoms suggestive for celiac disease but with 
negative serologic tests and mild duodenal damage (type 
I Marsh-Oberhuber classification). Our data show that 
mild duodenal damage is associated with microscopic 
colitis in more than the half of the investigated cases. 
This association may support the hypothesis of a 
new clinical and pathological entity, the “lymphocytic 
enterocolitis”.
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colitis in patients with mild duodenal damage: A new clinical 
and pathological entity (“lymphocytic enterocolitis”)? World J 
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INTRODUCTION
Celiac disease (CD) is a chronic inflammatory disease 
characterized by a pathological reaction against gluten 
proteins[1]. Currently, the prevalence of CD in the general 
population is proximally 1%, with a ratio between dia­
gnosed and undiagnosed cases of about 1:7[2,3]. CD 
presents often signs and symptoms such as chronic 
diarrhea, bloating, abdominal pain and malabsorption[4]. 
However, in a substantial number of cases, CD can 
manifest only extra­intestinal symptoms or signs, and 
it can be associated with autoimmune pathologies, as 
autoimmune thyroiditis, type I diabetes mellitus and 
rheumatoid arthritis[5,6]. The diagnosis of CD is based on 
the finding of positive antibody tests (anti­endomysium 
and anti­tissue transglutaminase), confirmed by bio­
psies taken during esophagogastroduodenoscopy 
(EGD) that reveal the characteristic duodenal damage. 
The Marsh­Oberhuber classification is usually used 
to grade the severity of duodenal lesions, with the 
type III representative of CD[7]. The search for human 
leukocyte antigen (HLA) haplotypes DQ2 and DQ8, due 
to its high negative predictive value, is used to exclude 
CD[8]. Nevertheless, there are patients with suggestive 
symptoms of CD, mild duodenal damage [i.e., an 
increase of intraepithelial lymphocytes (IEL)] defined 
type I, according to Marsh­Oberhuber classification, 
and negative antibody tests. This clinical condition, that 
does not conform with the diagnosis of CD, needs to be 
investigated for other causes[9]. 
Microscopic colitis (MC) is a chronic inflammatory 
bowel disease, distinct in lymphocytic colitis (LC)[10] 
and collagenous colitis (CC)[11]. The diagnosis of MC is 
obtained by multiple colonic mucosal biopsies taken 
during colonoscopy[12]. Typically, in CC, the histological 
feature is a thickening of the subepithelial collagen layer 
beneath the basal membrane, of more than 7­10 µm 
(0­3 µm in the normal colon)[13]. The histological feature 
of LC is the presence of more than 20 IEL/100 surface 
epithelial cells (< 5 IEL/100 in the normal colon)[14]. 
Paucicellular LC is a term used when the number of IEL 
is comprised between 5 IEL/100 and 20/100 surface 
epithelial cells. In MC, IEL are T­Lymphocyte CD3+ 
and CD8+, similar to those described in case of type I 
Marsh­Oberhuber lesions. Previously considered rare, 
MC is now a relatively common cause of chronic watery 
nonbloody diarrhea, especially in the elderly[15]. Both LC 
and CC are associated with autoimmune diseases and 
allergy[16]. Finally, it has been shown that patients with 
MC have an increased rate of HLA­DQ2 and HLA­DQ8 
positivity[17], even if this association is less strict than 
with CD. 
Although some authors reported an association 
between MC and type I Marsh­Oberhuber duodenal 
damage[18­23], the interpretation of this finding is poorly 
described. Nevertheless, there are few studies[24] that 
searched for the inverse association. 
The aim of this study was to evaluate, for the first 
time, the association between type I Marsh­Oberhuber 
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duodenal damage and MC, arguing for the existence of 
a possible “microscopic enterocolitis”[25,26]. 
MATERIALS AND METHODS
We retrospectively included 105 (86 females, mean age 
40.1 ± 13.7) consecutive patients with type I Marsh­
Oberhuber duodenal damage and negativity for anti­
endomysium (EmA) and anti­tissue transglutaminase 
(tTG) immunoglobulin (Ig)A antibodies. No sign of 
Whipple disease were reported in duodenal biopsies. 
Patients affected by small bowel bacterial overgrowth 
were excluded from the analysis. The analysis included 
patients observed in the period 1 January 2003­31 
December 2013 in the outpatients clinic of the Unit of 
Gastroenterology and Hepatology, Molinette Hospital, 
Turin, Italy.
In 5 cases of IgA deficiency, the genetic assessment 
(HLA­DQ2/DQ8) was performed: In 3, the result was 
negative while in the remaining 2 HLA­DQ2 positivity 
was found.
The following parameters were analyzed: Sex, age 
at execution of EGD, duodenal damage with number 
of IEL at biopsies, age at execution of colonoscopy, 
macroscopic and microscopic features of colonoscopy, 
family history of gastrointestinal and autoimmune 
diseases, smoking habits, dosage of erythrocyte sedi­
mentation rate (ESR), C­reactive protein (CRP) and 
anti­nuclear antibody (ANA), use of proton pump inhibi­
tors (PPIs) or nonsteroidal anti­inflammatory drugs 
(NSAIDs)[27], adverse reactions to drugs or foods, 
pathologies associated with CD or MC, living on a gluten­
free diet or on a gluten­low diet for at least 1 mo. Data 
on the prevalence of watery diarrhea, constipation, 
epigastric pain, abdominal pain, weight loss, nausea 
and/or vomiting, bloating, and asthenia were collected. 
Malabsorption was defined as the presence of at 
least one of these elements: Hemoglobin (Hb) < 12 
g/L and low levels of serum iron or folate or vitamin 
B12; hypoalbuminemia; weight loss > 10% without 
hypocaloric diet. Helicobacter pylori (H. pylori) infection 
was investigated by urea breath test and gastric 
biopsies. The previous eradication treatment of this 
infection, if any, was reported. 
The pharmacological anamnesis for assumption 
of prednisone, mesalamine, salazopyrin, budesonide, 
and antibiotics (rifaximin, ciprofloxacin, metronidazole) 
was conducted. Patients who took serotonin reuptake 
inhibitors or antiplatelets were excluded from the 
analysis.
Statistical analysis
For parametric data, we initially used the “normal 
probability plot”, to value a normal data distribution; in 
case of positive return, the Student T test to match the 
two subgroups was used.
For non­parametric data, the subgroups were 
matched with the Yates’ χ2 test or with the Fisher’s exact 
test if data were ≤ 5.
Confidence interval (CI) was set at 95%, with the 
statistical significance set at P value < 0.05. All statistical 
analyses were performed using MedCalc software 
(MedCalc Software, version 9.2.1.0).
RESULTS 
Overall, colonoscopy was performed in 59 patients, but 
in only 48 cases biopsies were taken along the entire 
colon. In the remaining 11 cases, biopsies were not 
taken or taken only in the left colon. The histological 
findings permitted to divide the cohort into two groups: 
That including 25 patients with diagnosis of MC and that 
including 23 patients without MC (Figure 1). 
Matching by age, patients who underwent colonos­
copy (42.7 ± 15.5 years) vs those who did not undergo 
colonoscopy (36.9 ± 10.6 years), a statistical difference 
was found (P = 0.039). On the contrary, there was no 
significant difference between the group of patients who 
did not undergo colonoscopy (36.9 ± 10.6 years) vs 
the group who underwent colonoscopy and executed 
multiple biopsies (40.4 ± 13.7 years) (P = 0.186). 
Considering the symptoms, there were no statistical 
differences between patients who did not undergo 
colonoscopy vs those who underwent colonoscopy and 
executed multiple biopsies (P = 0.09 and P = 0.14 for 
epigastric pain and diarrhea, respectively). Diarrhea 
was statistically more prevalent in MC group than in 
patients who did not undergo colonoscopy (P = 0.03). 
Patients who did not undergo colonoscopy vs those who 
underwent colonoscopy and executed multiple biopsies 
had not statistical differences when comparing the 
heterodimers HLA­DQ2 and HLA­DQ8 (P = 0.19). 
Among patients who underwent colonoscopy, an 
inflammatory pattern was found in 89.6% of cases. 
Focusing on the 25 patients with MC, the females to 
males ratio resulted 5:1 and the mean age was 40 
± 16.3 years. The diagnosis was LC in 13 cases, pau­
cicellular LC in 9, CC in 2, and undefined MC in the 
remaining patient. The average duodenal IEL were 
41.6/100 epithelial cells and colonic IELs were 25.4/100 
epithelial cells. Watery diarrhea was present in 17/25 
(68%) patients, abdominal pain in 16/25 (64%), 
weight loss in 11/25 (44%), nausea or vomiting in 7/25 
(28%), epigastric pain in 6/25 (24%), asthenia in 5/25 
(20%), bloating in 4/25 (16%), and gastroesophageal 
reflux disease (GERD) in 2/25 (8%). A family history 
of Crohn’s disease, thyroiditis, rheumatoid arthritis or 
spondylitis, was present in 1/25 (4%) patient for each 
one. Regarding smoking habits, 19/25 (76%) patients 
were non­smokers while the remaining 6 (24%) were 
smokers. ANA test resulted positive in 4/25 (16%) 
patients, ESR increased in 2/25 (8%), and CRP in 2/25 
(8%). Four out of twenty­five (16%) patients had a 
positive history of PPIs use, and 1/25 (4%) of NSAIDs 
use. Autoimmune thyroiditis was diagnosed in 4/25 
(16%) patients, asthma in 3/25 (12%), rheumatoid 
arthritis in 3/25 (12%). Anamnesis of adverse reactions 
to drugs or foods resulted in 10/25 (40%) patients. 
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Thirteen patients (52%) had HLA­DQ2 positivity, 8 
(32%) HLA­DQ2/DQ8 negativity, and 4 (16%) HLA­
DQ8 positivity. Regarding H. pylori infection, 19/25 
(76%) had negativity ab initio while 4 out of 6 with 
positivity (66.6%), eradicated the infection after anti­
biotic treatment. None of the tested patients had 
positivity at coproculture or at parasitological fecal test 
(6 and 2 cases, respectively). Fourteen (56%) patients 
undertook a gluten­free diet for at least 1 mo with a 
clinical improvement in 3/14 (21.4%). Malabsorption 
was observed in 12 (48%) patients. 
Among patients without MC, the female to male 
ratio resulted 3.8:1 and the mean age was 40.5 ± 13.7 
years. The diagnosis was of chronic and non­specific 
inflammation in 13 (56.5%) cases, there was a normal 
finding in 5 (21.7%), eosinophilic colitis in 2 (8.6%), 
Crohn’s disease in 2 (8.6%), and autoimmune enteritis 
in the last one (4.3%). The average duodenal IEL 
resulted 42.1/100 epithelial cells. Based on the available 
data, a family history of Crohn’s disease, rheumatoid 
arthritis or spondylitis was reported in one out of 23 
(4.3%) patients for each disease. Regarding smoking 
habits, 15/23 (65.2%) patients were non­smokers while 
the remaining 8 (34.8%) were smokers. Abdominal pain 
was present in 10/23 (43.4%) patients, watery diarrhea 
in 10/23 (43.4%), epigastric pain in 5/23 (21.7%), 
bloating in 5/23 (21.7%), asthenia in 4/23 (17.3%), 
nausea or vomiting in 4/23 (17.3%), GERD in 4/23 
(17.3%), constipation in 4/23 (17.3%), and weight 
loss in 3/23 (13.0%). ANA test resulted positive in 8/23 
(34.8%) patients, ESR and CPR was increased in 6/23 
(26.1%) and 5/23 (21.7%), respectively. A history of 
PPIs or NSAIDs use was reported in 6/23 (26.1%) and 
no patient, respectively. Autoimmune thyroiditis was 
reported in 3/23 (13%) of the patients, asthma in 2/23 
(8.6%), rheumatoid arthritis in 2/23 (8.6%), systemic 
erythematosus lupus (SLE), autoimmune hepatitis and 
multiple autoimmune diseases in 1/23 (4.3%) for each 
one. Adverse reactions to drugs or foods resulted in 
10/23 (43.4%) patients. Ten (43.4%) patients had HLA­
DQ2/DQ8 negativity, 9 (39.1%) had HLA­DQ2 positivity, 
3 (13%) HLA­DQ8 positivity, and one (4.3%) had HLA­
DQ2/DQ8 positivity. Regarding H. pylori infection, 15/23 
(65.2%) of the tested patients were negative ab initio, 
while 8/23 (34.8%) were positive. Of the latter group, 5 
out of 8 (62.5%) eradicated the infection after antibiotic 
treatment. None of the tested patients had positivity 
at coproculture or at parasitological fecal test (4 and 1 
case, respectively). 
Comparing patients with MC vs those without MC 
(Table 1), the only variables that had a statistical differ­
ence were weight loss (P = 0.01), more frequent in 
case of MC, and constipation (P = 0.04) more frequent 
in absence of MC. Diarrhea (P = 0.08), abdominal pain 
(P = 0.15), epigastric pain (P = 0.85), GERD (P = 0.33), 
autoimmune thyroiditis (P = 0.79), smoking habits (P 
= 0.66), asthma (P = 0.72), rheumatoid arthritis (P 
= 0.72), autoimmune hepatitis (P = 0.31), multiple 
autoimmune diseases (P = 0.35), HLA­DQ2 positivity 
(P = 0.51), HLA­DQ8 positivity (P = 0.79) did not reach 
statistical significance. 
Among patients suffering from MC, budesonide was 
used in 14 patients, of whom 13 (92.9%) responded to 
therapy; 8 patients used mesalamine, of them 4 (50%) 
responded to therapy; 4 patients used salazopyrin, with 
response in 2 (50%); 1 patient used prednisone, with 
response. No difference about the response to therapy 
resulted from the comparison between budesonide and 
mesalamine (P = 0.27), budesonide and salazopyrin (P 
= 0.41), budesonide and prednisone (P = 0.94). Among 
patients without MC, 7 used budesonide and 6/7 (85.7%) 
responded to therapy; 4 patients used prednisone 
without response; 6 patients used mesalamine with 
response in 3 (50%). 
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Patients with MC Patients without MC P value
  Watery diarrhea 17/25 (68%) 10/23 (43%) 0.08
  Abdominal pain 16/25 (64%) 10/23 (43%) 0.15
  Weight loss 11/25 (44%)   3/23 (13%) 0.01
  Nausea/vomiting   7/25 (28%)   4/23 (17%) 0.29
  Epigastric pain   6/25 (24%)   5/23 (21%) 0.85
  Asthenia   5/25 (20%)   4/23 (17%) 0.55
  Bloating   4/25 (16%)   5/23 (21%) 0.44
  GERD 2/25 (8%)   4/23 (17%) 0.33
  Constipation 0/25 (0%)   4/23 (17%) 0.04
  History of allergy 10/25 (40%) 10/23 (43%) 0.40
  PPIs use   4/25 (16%)   6/23 (26%) 0.44
  NSAIDs use 1/25 (4%) 0/23 (0%) 0.34
  ANA positivity   4/25 (16%)   8/23 (34%) 0.46
  ESR increased 2/25 (8%)   6/23 (26%) 0.13
  CRP increased 2/25 (8%)   5/23 (21%) 0.21
  Helicobacter 
  pylori infection 
  6/25 (24%)   8/23 (34%) 0.61
Table 1  Main clinical and laboratory parameters of enrolled 
patients
MC: Microscopic colitis; GERD: Gastroesophageal reflux disease; PPIs: 
Proton pump inhibitors; NSAIDs: Nonsteroidal anti-inflammatory drugs; 
ANA: Anti-nuclear antibody; ESR: Erythrocyte sedimentation rate; CRP: 
C-reactive protein.
52.10%
27.00%
10.40%
2.10%
4.20%
4.20%
Microscopic colitis
Normal findings
Crohn's disease
Chronic and non-specific
flogosis
Eosinophilic colitis
Autoimmune enteritis
Figure 1  Microscopic findings at colonoscopy (48 cases).
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DISCUSSION
In this study, we found a strong association between 
type I Marsh­Oberhuber duodenal damage and MC, 
mainly LC. More than half (52.1%) of the patients who 
underwent colonoscopy with multiple biopsies had MC. 
This percentage is significantly higher than the historical 
prevalence of MC in the general population (0.5%)[28]. 
An intriguing data was that LC and paucicellular LC, 
considered together, were diagnosed in much more 
cases than CC (22 vs 2, respectively). Usually, literature 
considered incidence and prevalence of CC higher than 
LC; however, more recent studies, according to our data, 
report that the incidence of LC is significantly rising[29].
Patients who underwent colonoscopy were signifi­
cantly older than those who did not undergo colono­
scopy. This could be partially explained considering the 
age as a parameter associated to augmented risk of 
malignancy. Hence, clinicians recurred to endoscopy 
in case of unexplained symptoms and increasing age. 
However, there was no difference in the median age 
between patients who did not undergo colonoscopy vs 
those who underwent colonoscopy with multiple biopsies. 
Considering biochemical results and symptoms 
among various groups, only chronic diarrhea was signi­
ficantly higher in patients with MC than in those who 
did not undergo colonoscopy (P = 0.03). Thus, in 
patients with mild duodenal damage only this symptom 
could predict MC. However, due to its multifactorial 
pathogenesis, the presence of diarrhea cannot be the 
only element to decide whether this type of patients 
should undergo colonoscopy with multiple biopsies. On 
the other hand, the absence of diarrhea cannot exclude 
the indication for colonoscopy with multiple biopsies, 
because only 5 out of 48 (10.4%) patients who had 
a colonoscopy with biopsies had normal microscopic 
findings, despite suffering also from abdominal pain, 
weight loss, constipation, positive fecal occult blood. 
The search for HLA­DQ2/DQ8 haplotypes seems to be 
useful, although the data in our retrospective study 
are not broad enough to provide definitive conclusions. 
Since this test has a very high negative predictive value 
in the diagnosis of CD, in patients with mild duodenal 
damage, negative serological tests for CD and the 
above reported symptoms, the negativity of HLA­DQ2/
DQ8 haplotypes can definitively exclude this disease 
and propel to search for other etiologies, as MC. 
The median age at which the diagnosis of MC was 
made in our patients (40 years) is lower than literature 
reports. Such finding may contrast with the idea of 
MC as disease of the elderly pointing out to a possible 
underestimation of this condition.
Another element that emerged from this study 
was the low prevalence of H. pylori­infection both 
in patients with MC (24%) than without MC (34%). 
The literature reports that H. pylori infection is related 
to duodenal lymphocytosis[9], which disappears after 
bacterial eradication. At the same time, we have recently 
found an inverse association between MC and H. pylori 
infection[29]. The results of the present study agree 
with the fact that in case of mild duodenal damage 
and MC the prevalence of H. pylori infection is lower 
than the general population (in our case 24% vs 
47%)[30]. Moreover, the rate of H. pylori eradication in 
this context, is similar to that obtained in the general 
population[31]. 
In our study, the role of pharmacological therapy in 
the pathogenesis of MC is not fully clear. In fact, only 4 
patients used PPIs and 1 patient used NSAIDs before 
the diagnosis of MC. This differs from the well­known 
data reporting that this type of medications are often 
implicated as a cause of MC[32], and could be explained 
by a β error (i.e., the failure to detect an effect that 
is present) due to the small sample size. Considering 
the outcome of therapy used to treat MC, budesonide 
emerged as the best treatment, due to a clinical 
improvement, in more than 90% of patients. Mesalamine 
seemed to be a valid therapeutic approach for less 
severe cases. According to some reports, our results 
confirm the appropriateness of this management[32].
Although in literature an association between MC 
and malabsorption is not reported[33], in our study 12 
(48%) patients presented signs of it. A potential disease 
of the small intestine, beyond the duodenum, could 
explain these features. More efforts are thus needed to 
understand this clinical condition.
This retrospective analysis shows inadequate 
habits of clinicians to search for a coproculture or a 
parasitological test; also the search for Giardia Lamblia 
was out of routine. Such investigations should play an 
important role in the attempt to identify the cause of 
duodenal damage. In fact, literature reports that the 
search for Giardia Lamblia or other pathogens should 
be included in the diagnostic work up of type I Marsh­
Oberhuber duodenal damage[34].
A potential limitation of our study is its retrospective 
design with a theoretical loss of balance on parameters 
analyzed. Nevertheless, we noticed uniform diagnostic 
and follow­up criteria.
In conclusion, MC is frequently associated with mild 
duodenal damage. This association may suggest the 
existence of a “microscopic enterocolitis”, and specifically 
of a “lymphocytic enterocolitis”, that involves the 
entire gastrointestinal tract. It is advisable to perform 
a colonoscopy with biopsies in all patients with type I 
Marsh­Oberhuber duodenal damage and symptoms as 
chronic diarrhea, abdominal or epigastric pain, loss of 
weight, after exclusion of standard causes.
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The diagnosis of celiac disease (CD) is based on the finding of positive antibody 
tests (anti-endomysium and anti-tissue transglutaminase), confirmed by 
biopsies that reveal the characteristic duodenal damage. The Marsh-Oberhuber 
classification is usually used to grade the severity of duodenal lesions, with the 
type III representative of CD. Nevertheless, there are patients with suggestive 
symptoms of CD, mild duodenal damage [i.e., an increase of intraepithelial 
lymphocytes (IEL)] defined type I, according to Marsh-Oberhuber classification, 
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and negative antibody tests. This clinical condition, that does not conform 
with the diagnosis of CD, needs to be investigated for other causes as well as 
for comorbidities. Microscopic colitis (MC), previously considered rare, was 
demonstrated as a relatively common cause of chronic, watery, diarrhoea. While 
some isolated studies reported some association between MC and Marsh I 
duodenal damage, the interpretation of this finding is poorly described. 
Research frontiers
To date, scarce information is available on the association between mild 
duodenal damage and MC. 
Innovations and breakthroughs
This study is the first showing that type I Marsh-Oberhuber duodenal damage 
is strongly associated with MC, mainly lymphocytic colitis (LC). More than half 
(52.1%) of the patients who underwent colonoscopy with multiple biopsies had 
MC. This percentage is significantly higher than prevalence of MC in the general 
population (0.5%). This association supports the hypothesis of a link between 
these two entities.
Applications
These findings, of association between type I Marsh-Oberhuber duodenal 
damage and MC, may suggest the existence of a “microscopic enterocolitis”, 
and specifically of a “lymphocytic enterocolitis”, that involves the entire gastroin-
testinal tract. It is advisable to perform a colonoscopy with biopsies in all patients 
with type I Marsh-Oberhuber duodenal damage and symptoms as chronic 
diarrhea, abdominal or epigastric pain, loss of weight, after exclusion of standard 
causes.
Terminology
The Marsh-Oberhuber classification is usually used to grade the severity of 
duodenal lesions, with the type III representative of CD. There are patients 
with suggestive symptoms of CD, mild duodenal damage (i.e., an increase 
of IEL) defined type I, according to Marsh-Oberhuber classification, and 
negative antibody tests, that do not conform with the diagnosis of CD. MC is 
a chronic inflammatory bowel disease, distinct in LC and collagenous colitis. 
The histological feature of LC is the presence of more than 20 IEL/100 surface 
epithelial cells (< 5 IEL/100 in the normal colon). Paucicellular LC is a term used 
when the number of IEL is comprised between 5 IEL/100 and 20/100 surface 
epithelial cells. In MC, IEL are T-Lymphocyte CD3+ and CD8+, similar to those 
described in case of type I Marsh-Oberhuber lesions. Here we report for the first 
time the association between type I Marsh-Oberhuber duodenal damage and 
MC, arguing for the existence of a possible “microscopic enterocolitis”.
Peer-review
This is an interesting manuscript.
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